Navigation Links
Pancreatic Cancer Treatment Market Size Worth $4.2 Billion by 2025: Grand View Research, Inc.
Date:3/14/2017

SAN FRANCISCO, March 14, 2017 /PRNewswire/ --

The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period.

Continue Reading
Grand View Research Logo
Grand View Research Logo

     (Logo: http://photos.prnewswire.com/prnh/20150105/723757)

According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.

Browse full research report with TOC on "Pancreatic Cancer Treatment Market Analysis By Affected Region (Exocrine, Endocrine), By Type (Chemotherapy, Targeted Therapy, Others), By Region (North America, Europe, Asia Pacific, Latin America And MEA), And Segment Forecasts, 2014 - 2025" at: http://www.grandviewresearch.com/industry-analysis/pancreatic-cancer-treatment-market

Further key findings from the report suggest: 

  • The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting for more than 95% of the overall pancreatic cancer types
  • Among the treatment types, targeted therapy occupied the largest share since it is considered as the most effective treatment option, which blocks the growth and spread of cancer cells without damaging healthy cells
  • North America dominated the segment with the largest revenue share in 2015 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure
  • Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment
  • Some of the major companies operating in this market are, but are not limited to, Eli Lilly and Company; Celgene Corporation; F. Hoffmann-La Roche AG; Amgen, Inc.; Novartis AG; PharmaCyte Biotech, Inc.; Clovis Oncology; Teva Pharmaceutical Industries Ltd.; Merck & Co., Inc.; and Pfizer, Inc.

Browse related reports by Grand View Research: 


Grand View Research has segmented the pancreatic cancer treatment market on the basis of affected region, treatment, and region: 

  • Pancreatic Cancer Treatment Affected Region Outlook (Revenue, USD Million, 2014 - 2025)
    • Exocrine
    • Endocrine
  • Pancreatic Cancer Treatment Outlook (Revenue, USD Million, 2014 - 2025)
    • Chemotherapy
    • Targeted Therapy
    • Others
  • Pancreatic Cancer Treatment Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • China
      • Japan
    • Latin America
      • Brazil
      • Mexico
    • MEA
      • South Africa

Read Our Blog: Pancreatic Cancer Treatment Market: Driven by the Ongoing Unhealthy Lifestyle

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com

Web: http://www.grandviewresearch.com


'/>"/>
SOURCE Grand View Research, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
2. Halozymes Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer
3. Pancreatic Cancer Advocates Call on Congress to Protect Medical Research Funding From Sequestration Cuts
4. Suit filed for Pancreatic Cancer By Use of Byetta, Januvia and Janumet
5. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
6. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
7. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
8. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
9. Byetta Lawsuit News: Bernstein Liebhard LLP Notes Approval of Master Complaint in Federal Byetta Pancreatic Cancer Litigation
10. Clinical Trial Participation Today May Lead To Future Breakthroughs In Pancreatic Cancer, One Of The Nations Deadliest Cancers
11. Xlumena Announces Initial Commercial Use of its First-in-Class AXIOS Stent and Delivery System for Treatment of Pancreatic Pseudocysts and Fluid Collections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
(Date:9/22/2017)... , Sept. 22, 2017 AVACEN Medical ... device is now successfully helping those with the widespread ... Fibromyalgia diagnosed Amanda in Essex, England ... and washing my hair, experiencing no sleep at all, ... painful spasm… I cannot recommend [the AVACEN 100] enough, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term ... long-term care insurance companies have a waiver for care if the client has a ... when the family pays for care, is often waived, so the benefits from their ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):